A Three-Way Combinatorial CRISPR Screen for Analyzing Interactions among Druggable Targets

Area of Science:

• * Molecular Biology
• * Genetics
• * Bioinformatics

Background:

• * Identifying synergistic drug combinations is crucial for effective cancer and neurodegenerative disease therapies.
• * Current methods struggle with the complexity of high-order genetic interactions.

Purpose of the Study:

• * To develop a CRISPR-based system for efficient, large-scale screening of multi-gene knockout combinations.
• * To identify pairwise and three-way synergistic therapeutic targets for cancer and Parkinson's disease.

Main Methods:

• * Engineered CRISPR system for assembling barcoded, high-order combinatorial guide RNA libraries.
• * Systematic screening to identify synergistic gene interactions.
• * Validation of identified double- and triple-combination regimens in cellular models.

Main Results:

• * Successfully identified synergistic therapeutic target combinations.
• * Validated double- and triple-drug regimens effectively suppressed cancer cell growth.
• * Demonstrated protection against Parkinson's disease-associated toxicity using identified combinations.

Conclusions:

• * The developed CRISPR system overcomes challenges in screening high-order genetic combinations.
• * Enables discovery of rare synergistic interactions between druggable targets.
• * Offers a powerful platform for uncovering novel combination therapies for complex diseases.